User login
FROM SABCS 2015 – A survey of Oncology Practice board members, including Dr. William J. Gradishar, Betsy Bramsen Professor of Breast Oncology, Northwestern University, Chicago, and medical oncologists at the Cleveland Clinic who will be attending the San Antonio Breast Cancer Symposium, revealed several anticipated studies from this year’s symposium, set to begin on Wednesday, Dec. 9. Titles, and links to abstracts if available, are listed below:
• S2-02 The Impact of Adjuvant Denosumab on Disease-Free Survival: Results from 3,425 Postmenopausal Patients of the ABCSG-18 Trial.
• S2-05 Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/-carboplatin and/or bevacizumab in triple-negative breast cancer: Outcomes from CALGB 40603 (Alliance).
• S5-05 Trastuzumab emtansine improves overall survival versus treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer: Final overall survival results from the phase III TH3RESA study.
• S1-05 Prophylactic beta blockade preserves left ventricular ejection fraction in HER2-overexpressing breast cancer patients receiving trastuzumab: Primary results of the MANTICORE randomized controlled trial.
• S1-07 A phase III trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X, JBCRG-04).
• S4-01 Identification of early versus late drivers of breast tumors and metastasis.
• S5-07 Preliminary efficacy and safety of pembrolizumab (MK-3475) in patients with PD-L1–positive, estrogen receptor-positive (ER+)/HER2-negative advanced breast cancer enrolled in KEYNOTE-028.
• S1-09 A comparison of the diagnostic performance of 2D synthetic mammography versus digital breast tomosynthesis in 2,500 patients.
• S6-01 PIK3CA status in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-resistant HR+/HER2– advanced breast cancer (BC): First results from the randomized, phase III BELLE-2 trial.
• S5-04 Ten-year follow-up of the BCIRG-006 trial comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC®T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC®TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2+ early breast cancer patients.
• S3-05 Higher 10-year overall survival after breast conserving therapy compared to mastectomy in early stage breast cancer: a population-based study with 37,207 patients.
• S1-04 Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase Ib JAVELIN solid tumor trial.
FROM SABCS 2015 – A survey of Oncology Practice board members, including Dr. William J. Gradishar, Betsy Bramsen Professor of Breast Oncology, Northwestern University, Chicago, and medical oncologists at the Cleveland Clinic who will be attending the San Antonio Breast Cancer Symposium, revealed several anticipated studies from this year’s symposium, set to begin on Wednesday, Dec. 9. Titles, and links to abstracts if available, are listed below:
• S2-02 The Impact of Adjuvant Denosumab on Disease-Free Survival: Results from 3,425 Postmenopausal Patients of the ABCSG-18 Trial.
• S2-05 Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/-carboplatin and/or bevacizumab in triple-negative breast cancer: Outcomes from CALGB 40603 (Alliance).
• S5-05 Trastuzumab emtansine improves overall survival versus treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer: Final overall survival results from the phase III TH3RESA study.
• S1-05 Prophylactic beta blockade preserves left ventricular ejection fraction in HER2-overexpressing breast cancer patients receiving trastuzumab: Primary results of the MANTICORE randomized controlled trial.
• S1-07 A phase III trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X, JBCRG-04).
• S4-01 Identification of early versus late drivers of breast tumors and metastasis.
• S5-07 Preliminary efficacy and safety of pembrolizumab (MK-3475) in patients with PD-L1–positive, estrogen receptor-positive (ER+)/HER2-negative advanced breast cancer enrolled in KEYNOTE-028.
• S1-09 A comparison of the diagnostic performance of 2D synthetic mammography versus digital breast tomosynthesis in 2,500 patients.
• S6-01 PIK3CA status in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-resistant HR+/HER2– advanced breast cancer (BC): First results from the randomized, phase III BELLE-2 trial.
• S5-04 Ten-year follow-up of the BCIRG-006 trial comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC®T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC®TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2+ early breast cancer patients.
• S3-05 Higher 10-year overall survival after breast conserving therapy compared to mastectomy in early stage breast cancer: a population-based study with 37,207 patients.
• S1-04 Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase Ib JAVELIN solid tumor trial.
FROM SABCS 2015 – A survey of Oncology Practice board members, including Dr. William J. Gradishar, Betsy Bramsen Professor of Breast Oncology, Northwestern University, Chicago, and medical oncologists at the Cleveland Clinic who will be attending the San Antonio Breast Cancer Symposium, revealed several anticipated studies from this year’s symposium, set to begin on Wednesday, Dec. 9. Titles, and links to abstracts if available, are listed below:
• S2-02 The Impact of Adjuvant Denosumab on Disease-Free Survival: Results from 3,425 Postmenopausal Patients of the ABCSG-18 Trial.
• S2-05 Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/-carboplatin and/or bevacizumab in triple-negative breast cancer: Outcomes from CALGB 40603 (Alliance).
• S5-05 Trastuzumab emtansine improves overall survival versus treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer: Final overall survival results from the phase III TH3RESA study.
• S1-05 Prophylactic beta blockade preserves left ventricular ejection fraction in HER2-overexpressing breast cancer patients receiving trastuzumab: Primary results of the MANTICORE randomized controlled trial.
• S1-07 A phase III trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X, JBCRG-04).
• S4-01 Identification of early versus late drivers of breast tumors and metastasis.
• S5-07 Preliminary efficacy and safety of pembrolizumab (MK-3475) in patients with PD-L1–positive, estrogen receptor-positive (ER+)/HER2-negative advanced breast cancer enrolled in KEYNOTE-028.
• S1-09 A comparison of the diagnostic performance of 2D synthetic mammography versus digital breast tomosynthesis in 2,500 patients.
• S6-01 PIK3CA status in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-resistant HR+/HER2– advanced breast cancer (BC): First results from the randomized, phase III BELLE-2 trial.
• S5-04 Ten-year follow-up of the BCIRG-006 trial comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC®T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC®TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2+ early breast cancer patients.
• S3-05 Higher 10-year overall survival after breast conserving therapy compared to mastectomy in early stage breast cancer: a population-based study with 37,207 patients.
• S1-04 Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase Ib JAVELIN solid tumor trial.